Utility of PCD Diagnostics to Improve Clinical Care

Status Recruiting

Clinical Trial Summary

This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus cavity. Individuals with PCD characteristically have low levels, but this testing does not have extensive data from everyday clinical practice. The objective of this proposal is to improve the diagnostic approach to children and adults with clinical concerns for primary ciliary dyskinesia (PCD).

Clinical Trial Description

This is an observational study to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). Participant selection will be on a referral basis for the consideration of a clinical suspicion for PCD. Participants will be identified by pulmonary providers that consider testing for PCD based on the clinical symptoms of the participant. These providers will then refer for enrollment in the study based on the clinical considerations for a diagnosis of PCD. Participants will be consented during the time of testing at the Pulmonary department. Any patient referred by a clinician for concerns for PCD, including those who have had PCD genetics sent, or a ciliary biopsy performed will be enrolled in the study. In addition, any participant who is referred for nasal nitric oxide testing and meets the inclusion and exclusion criteria for this testing, will also need to provide informed consent and be enrolled in the Nasal NO REDCap registry. This equipment is not currently FDA approved or CLIA certified for PCD diagnostic testing and therefore referring clinicians will be informed that the results of this test should not influence clinical decision making regarding the diagnosis of PCD. However, there is growing evidence that this testing has utility as a non-invasive screening tool for PCD and continued data from the general pediatric pulmonary population is needed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05889013
Study type	Observational [Patient Registry]
Source	Connecticut Children's Medical Center
Contact	Melanie S Collins, MD
Phone	860-545-9440
Email	mcollin@connecticutchildrens.org
Status	Recruiting
Phase
Start date	September 27, 2023
Completion date	June 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01246258` - Otolith Function in Patients With Primary Ciliary Dyskinesia	N/A
Completed	`NCT04858191` - Utilizing Hyperpolarized 129Xe Magnetic Resonance Imaging in Children With Primary Ciliary Dyskinesia
Completed	`NCT05712798` - Physiological Responses to Exercise Tests in Primary Ciliary Dyskinesia Compared With Healthy Individuals
Completed	`NCT03370029` - Respiratory Muscle Strength, Exercise Capacity and Physical Activity Levels in Children Primary Ciliary Dyskinesia
Completed	`NCT00368446` - Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease
Recruiting	`NCT05374720` - Analysis of the Molecular Composition of Tubal Cilia in Patients With or Without Ectopic Pregnancy	N/A
Completed	`NCT05816876` - Muscle Function, Exercise Capacity and Physical Activity Level in Primary Ciliary Dyskinesia and Kartagener Syndrome
Recruiting	`NCT04717115` - Genotype/Phenotype Correlation With Focus on Lung Function in Primary Ciliary Dyskinesia (PCD)
Recruiting	`NCT03279965` - MRI in Cystic Fibrosis and Primary Ciliary Dyskinesia	N/A
Recruiting	`NCT03320382` - Multiple Breath Washout, a Clinimetric Dataset
Recruiting	`NCT04602481` - COVID-19 in People With Primary Ciliary Dyskinesia
Not yet recruiting	`NCT02704455` - Registry Study on Primary Ciliary Dyskinesia in Chinese Children	N/A
Completed	`NCT00323167` - Rare Genetic Disorders of the Breathing Airways
Recruiting	`NCT05932316` - Evaluating Bronchodilator Response in Patients With Bronchiectasis	N/A
Completed	`NCT03832491` - Effect of Game Based Approach on Oxygenation, Functional Capacity and Quality of Life in Primary Ciliary Dyskinesia	N/A
Recruiting	`NCT05951478` - DCP (RaDiCo Cohort) (RaDiCo-DCP)
Completed	`NCT06028607` - Feasibility of Consumption of Nutritional Supplementation in Primary Ciliary Dyskinesia	N/A
Recruiting	`NCT05685186` - A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
Recruiting	`NCT05161858` - Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia
Recruiting	`NCT04611516` - The Ear-Nose-Throat (ENT) Prospective International Cohort of PCD Patients (EPIC-PCD)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.